Does the Sex of a Cell Matter in Research?
Credit: Paula Burch-Celentano
Over the last decade, many drugs that have been pulled from the market due to toxicity were withdrawn because they affected women more than men. It turns out, the studies that brought the drugs to market were designed using only male cells and animal models, a common flaw a Tulane endocrinologist is working to help correct.
“We really need to study both sexes,” says Dr. Franck Mauvais-Jarvis, a leading voice in the debate to bring sex parity to pre-clinical research. “The focus on a single sex threatens to limit the impact of research findings as results may be relevant to only half of the population.”
Mauvais-Jarvis, a professor of endocrinology at Tulane University School of Medicine, is the lead author of a newly published article in the journal Cell Metabolism to help scientists who study obesity, diabetes or other metabolic diseases better account for inherent sex differences in research.
While the National Institutes of Health recently mandated researchers consider sex as a biological variable by including both sexes in pre-clinical research, there is little guidance in designing studies to fully consider sex differences in underlying biological mechanisms. The article outlines the causes of sex differences in research models and the methods for investigators to account for these factors.
Mauvais-Jarvis’ goal is to help investigators better understand that sex differences are not simply a superficial aspect of research that only account for different sets of hormones. He maintains that male and female are two different biological systems.
“Sex differences are at the core of the mechanism for biological traits and disease,” Mauvais-Jarvis says. “We believe that the incorporation of appropriately designed studies on sex differences in metabolism and other fields will accelerate discovery and enhance our ability to treat disease. This is the fundamental basis of precision medicine.”
This article has been republished from materials provided by Tulane University. Note: material may have been edited for length and content. For further information, please contact the cited source.
Uptake of Controlled Release Drug Delivery Technology Set to Increase?News
The increasing access to healthcare facilities and the bolstering need for drugs to be used orally has been driving the consumption of generic drugs among people across the world, which, in turn, is fueling the need for controlled release technology for drug delivery to suffice the availability of drugs in small dosages.READ MORE
New Automated Screening Method for Identifying Drug CandidatesNews
Scientists at DESY have developed a new method that enables automated and fast screening of promising drug candidates.READ MORE
Metabolomic Profiling Identifies Taurine as New MS TherapeuticNews
New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. The discovery also highlights the potential for a technique called “metabolomic profiling,” which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.READ MORE